TY - JOUR
T1 - Oligomerization Alters Binding Affinity between Amyloid Beta and a Modulator of Peptide Aggregation
AU - Hilt, Silvia
AU - Rojalin, Tatu
AU - Viitala, Tapani
AU - Koivuniemi, Artturi
AU - Bunker, Alex
AU - Wachsmann-Hogiu, Sebastian
AU - Kálai, Tamás
AU - Hideg, Kálmán
AU - Yliperttula, Marjo
AU - Voss, John C.
N1 - Funding Information:
Financial support by the Academy of Finland (Grant Nos. 263861 and 292253), Tekes, The Finnish Funding Agency for Innovation EV-Extra-Tox project, and the Professor Pool, Orion Research Foundation, are gratefully acknowledged. CSC, The IT Center for Science (Helsinki, Finland), is acknowledged for providing supercomputer facilities. We also acknowledge support from the UC Davis STAIR Program to J.C.V. We thank Dr. David Gae for his assistance in rendering molecular structures.
Publisher Copyright:
© 2017 American Chemical Society.
PY - 2017/11/2
Y1 - 2017/11/2
N2 - The soluble oligomeric form of the amyloid beta (Aβ) peptide is the major causative agent in the molecular pathogenesis of Alzheimer's disease (AD). We have previously developed a pyrroline-nitroxyl fluorene compound (SLF) that blocks the toxicity of Aβ. Here we introduce the multiparametric surface plasmon resonance (MP-SPR) approach to quantify SLF binding and its effect on the self-association of the peptide via a label-free, real-time approach. Kinetic analysis of SLF binding to Aβ and measurements of layer thickness alterations inform on the mechanism underlying the ability of SLF to inhibit Aβ toxicity and its progression toward larger oligomeric assemblies. Depending on the oligomeric state of Aβ, distinct binding affinities for SLF are revealed. The Aβ monomer and dimer uniquely possess subnanomolar affinity for SLF via a nonspecific mode of binding. SLF binding is weaker in oligomeric Aβ, which displays an affinity for SLF on the order of 100 μM. To complement these experiments we carried out molecular docking and molecular dynamics simulations to explore how SLF interacts with the Aβ peptide. The MP-SPR results together with in silico modeling provide affinity data for the SLF-Aβ interaction and allow us to develop a new general method for examining protein aggregation.
AB - The soluble oligomeric form of the amyloid beta (Aβ) peptide is the major causative agent in the molecular pathogenesis of Alzheimer's disease (AD). We have previously developed a pyrroline-nitroxyl fluorene compound (SLF) that blocks the toxicity of Aβ. Here we introduce the multiparametric surface plasmon resonance (MP-SPR) approach to quantify SLF binding and its effect on the self-association of the peptide via a label-free, real-time approach. Kinetic analysis of SLF binding to Aβ and measurements of layer thickness alterations inform on the mechanism underlying the ability of SLF to inhibit Aβ toxicity and its progression toward larger oligomeric assemblies. Depending on the oligomeric state of Aβ, distinct binding affinities for SLF are revealed. The Aβ monomer and dimer uniquely possess subnanomolar affinity for SLF via a nonspecific mode of binding. SLF binding is weaker in oligomeric Aβ, which displays an affinity for SLF on the order of 100 μM. To complement these experiments we carried out molecular docking and molecular dynamics simulations to explore how SLF interacts with the Aβ peptide. The MP-SPR results together with in silico modeling provide affinity data for the SLF-Aβ interaction and allow us to develop a new general method for examining protein aggregation.
UR - http://www.scopus.com/inward/record.url?scp=85032833755&partnerID=8YFLogxK
U2 - 10.1021/acs.jpcc.7b06164
DO - 10.1021/acs.jpcc.7b06164
M3 - Article
AN - SCOPUS:85032833755
SN - 1932-7447
VL - 121
SP - 23974
EP - 23987
JO - Journal of Physical Chemistry C
JF - Journal of Physical Chemistry C
IS - 43
ER -